Abivax SA is a clinical-stage biotechnology company founded in 2013 and headquartered in Paris, France. The company is dedicated to the discovery and development of novel therapies in the fields of immunology, viral infections and oncology. Abivax completed its initial public offering on the NASDAQ under the ticker ABVX in 2021, reflecting its ambition to expand research collaboration and clinical development internationally.
Abivax’s lead asset, obefazimod (formerly ABX464), is a first-in-class small molecule designed to modulate RNA biogenesis and resolve chronic inflammation. Obefazimod is being evaluated in multiple indications, including ulcerative colitis, Crohn’s disease, rheumatoid arthritis and certain viral infections such as HIV. Preclinical and clinical data have demonstrated the drug candidate’s potential to stimulate microRNA-124 production, thereby reducing pro-inflammatory cytokine levels and promoting tissue repair.
In addition to its flagship program, Abivax is advancing a diversified pipeline of discovery-stage compounds targeting oncology and immune-mediated diseases. The company operates research laboratories in Paris and maintains a subsidiary in the United States to support its North American clinical trials. Collaborative partnerships with academic institutions and contract research organizations underpin its translational research strategy and streamline regulatory submissions across Europe and the Americas.
Abivax is led by co-founder and Chief Executive Officer Frédéric Montagnon, whose background spans pharmaceutical development and venture creation. The management team includes seasoned executives in clinical operations, regulatory affairs and commercial strategy, complemented by a scientific advisory board of experts in immunology and infectious diseases. Together, they steer Abivax’s mission to deliver innovative therapies for patients with high-unmet medical needs.
AI Generated. May Contain Errors.
